smartCrystal combination technology - scale up from lab to pilot scale and long term stability

被引:32
作者
Al Shaal, L. [1 ]
Mueller, R. H. [1 ]
Shegokar, R. [1 ]
机构
[1] Free Univ Berlin, Inst Pharm, Dept Pharmaceut Biopharmaceut & NutriCosmet, D-12169 Berlin, Germany
来源
PHARMAZIE | 2010年 / 65卷 / 12期
关键词
DRUG-DELIVERY; PARTICLE-SIZE; CELL-LINES; NANOSUSPENSIONS; APIGENIN; FLAVONOIDS; NANOCRYSTALS; SOLUBILITY; STABILIZATION; DISSOLUTION;
D O I
10.1691/ph.2010.0181
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
The production of nanocrystals was scaled up from lab scale (20 g) to pilot scale (3 kg), scale up factor 150. The flavonoid apigenin was used as model compound, with potential for pharma, cosmetic and nutraceutical products. Lab scale production was performed by high pressure homogenization (HPH), pilot scale by applying the smartCrystal combination technology (CT), combining pearl milling and a subsequent HPH (1 cycle, 300 bar). The obtained particle sizes were compared on the basis of photon correlation spectroscopy (PCS), laser diffractometry (LD) and light microscopy. The results showed, that assessment of successful scale up depends on the characterization method used, e.g., PCS covering only a part of the particle size range (3 nm-3 mu m) of the population, or LD the full size distribution. Long-term stability was predicted on zeta potential (ZP) measurements. Lab and pilot scale possessed sufficiently high ZP values (> 30 mV) for a stable dispersion, but the ZP values were different (5-7 mV). This was explained by differences in the Stern/Nernst potential of the nanocrystals, potentially due to different levels in the crystals where they break in a high energy process (HPH) versus a low energy size reduction (pearl mill). Independent on the production method and batch size, the nanosuspensions proved to be physically stable for 6 months at storage temperatures 4 degrees C, room temperature and 40 degrees C.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 45 条
[1]
Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application [J].
Agnihotri, Sagar M. ;
Vavia, Pradeep R. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2009, 5 (01) :90-95
[2]
THE RELATIONSHIP BETWEEN PARTICLE-SIZE AND SOLUBILITY [J].
BUCKTON, G ;
BEEZER, AE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 82 (03) :R7-R10
[3]
Complexes of Al(III) with 3′4′-dihydroxy-flavone:: characterization, theoretical and spectroscopic study [J].
Cornard, JP ;
Boudet, AC ;
Merlin, JC .
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2001, 57 (03) :591-602
[4]
Datta BK, 2004, PHARMAZIE, V59, P222
[5]
Towards a photophysical model for 5-hydroxyflavone [J].
del Valle, JC .
JOURNAL OF CHEMICAL PHYSICS, 2006, 124 (10)
[6]
Acidichromism and ionochromism of luteolin and apigenin, the main components of the naturally occurring yellow weld: A spectrophotometric and fluorimetric study [J].
Favaro, G. ;
Clementi, C. ;
Romani, A. ;
Vickackaite, V. .
JOURNAL OF FLUORESCENCE, 2007, 17 (06) :707-714
[7]
FICHERA MA, 2004, EFFECT 4000 BAR HOMO
[8]
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery [J].
Ganta, Srinivas ;
Paxton, James W. ;
Baguley, Bruce C. ;
Garg, Sanjay .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) :179-186
[9]
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions [J].
Gao, Lei ;
Zhang, Dianrui ;
Chen, Minghui ;
Duan, Cunxian ;
Dai, Wenting ;
Jia, Lejiao ;
Zhao, Wenfa .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 355 (1-2) :321-327
[10]
Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine [J].
Hecq, J ;
Deleers, M ;
Fanara, D ;
Vranckx, H ;
Amighi, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) :167-177